Biotech firm's shares plummet as cat-allergy study fails

Discussion in 'Market News' started by Lily, Jun 20, 2016.

  1. Lily

    Lily Forum Member

    Aug 29, 2015
    Likes Received:
    Circassia Pharmaceuticals loses two-thirds of its value after significant placebo effect halts trial of vaccine for sufferers

    An Oxford company hailed as a star of British biotechnology lost almost two-thirds of its stock market value on Monday after it revealed that its experimental cat allergy treatment had failed in a late-stage trial.

    Circassia Pharmaceuticals floated on the stock exchange in 2014 and was seen as one of the great hopes of the sector for its research into cat allergies, which affect 24 million people in the US alone.

    Related: Scientists link allergies to hyperactive immune cells in babies' cord blood

    Related: The day the NHS saved my life: rescuing a kitten nearly killed me

    Continue reading...

Share This Page

free forex signals